THERAPEUTIC MODALITIES Archives

In Vivo CAR-T: An Integrated Framework

In Vivo CAR-T: An Integrated Framework from Preclinical Development to Clinical Bioanalysis Opportunities and Challenges in In Vivo CAR-T Development...

EpCAM-CD3 BsAb-Encoding mRNA Suppresses Lung Tumors

Bispecific antibodies have emerged as an important modality in oncology, although their broader application can be limited by manufacturing complexity...

Synthetic-Lethality Screening with PARP1 inhibition

PARP1 plays a central role in DNA repair and is a well-established target across multiple cancer types. Understanding the vulnerabilities...

In Vitro and In Vivo Efficacy of CAR-T Delivery

Targeted lipid nanoparticles (tLNPs) are advancing in vivo CAR-T therapies by facilitating the in situ generation of CAR-T effectors, offering...

In Vivo Evaluation of VEGF-Targeted Bispecific Antibodies

As PD-1/PD-L1 x VEGF-targeted bispecific antibodies gain momentum in oncology, selecting the right preclinical models is becoming increasingly important. These...

In Vivo CAR-T Preclinical Evaluation Platform

CAR-T therapies have transformed the treatment of hematologic malignancies, yet complex manufacturing, long production timelines, and high costs continue to...

Advancing Conjugated Therapeutics: From ADC Innovation to Integrated Bioanalysis Strategies

Conjugated therapeutics, including antibody-drug conjugates (ADCs) and antibody-oligonucleotide conjugates (AOCs), are reshaping the future of targeted therapies and driving new...